This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Weitz, J. I. Search for Related Content PubMed Articles by Weitz, J. I. Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:721.)
© 2007 American Heart Association, Inc.

Brief Reviews

Emerging Anticoagulant Drugs

Jeffrey I. Weitz

From the Henderson Research Centre and Departments of Medicine and Biochemistry and Medical Sciences, McMaster University, Hamilton, Ontario, Canada.

Correspondence to Dr Jeffrey Weitz, Henderson Research Centre, 711 Concession St, Hamilton, Ontario, L8V 1C3, Canada. E-mail jweitz@thrombosis.hhscr.org

ATVB In Focus

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Nowhere is there more clinical trial activity than in the field of anticoagulant therapy. Numerous parenteral and oral anticoagulants are currently undergoing phase II and III evaluation, and many more drugs are in the pipeline. Natural anticoagulants isolated from hematophagous organisms and advances in structure-based drug design have helped to identify new anticoagulant targets and novel mechanisms of action. How can we keep up with this rapidly moving field? A new series, entitled "Emerging Anticoagulant Drugs", will address this need. With invited articles appearing periodically over the next 12 months, international experts will review the progress in the anticoagulant arena. Each paper will focus on a different drug target.

See page 722

The first article in this series concentrates on factor IXa. As the enzyme component of intrinsic tenase, the complex of factor IXa bound to factor VIIIa on an anionic phospholipid surface, factor IXa plays a critical role in the amplification of coagulation. The factor VIIa/tissue factor complex initiates coagulation by activating factor X and triggers the generation of small amounts of thrombin, which then activates platelets and factors VIII and V. With further factor X activation by the factor VIIa/tissue factor complex blocked by tissue factor pathway inhibitor, intrinsic tenase amplifies factor Xa generation to produce a burst of thrombin.

The review by Howard and colleagues suggests that factor IXa, critically positioned upstream to factor X, is an attractive target for new anticoagulant drugs. Factor IXa inhibitors attenuate the amplification of coagulation, but can this be done safely . . . [Full Text of this Article]

Related Article:

Factor IXa Inhibitors as Novel Anticoagulants

Emily L. Howard, Kristian C.D. Becker, Christopher P. Rusconi, and Richard C. Becker
Arterioscler Thromb Vasc Biol 2007 27: 722-727. [Abstract] [Full Text] [PDF]